Pfiz­er chal­lenges Mod­er­na Covid vac­cine patents be­fore Patent Tri­al and Ap­peal Board

Pfiz­er is chal­leng­ing the Covid-19 vac­cine patents that Mod­er­na has ac­cused the com­pa­ny of in­fring­ing be­fore the Patent Tri­al and Ap­peal Board (PT­AB), ar­gu­ing that the patents are too broad and hinge on in­for­ma­tion about mR­NA that was known well be­fore the de­vel­op­ment of the vac­cines.

Pfiz­er and BioN­Tech ar­gue in two sep­a­rate pe­ti­tions for in­ter partes re­view filed with the PT­AB Mon­day that Mod­er­na is at­tempt­ing to “coopt an en­tire field of mR­NA tech­nol­o­gy.” The PT­AB chal­lenges re­late to the law­suit Mod­er­na brought against Pfiz­er and BioN­Tech in Au­gust 2022, al­leg­ing that their vac­cine Comir­naty copied Mod­er­na’s vac­cine tech­nol­o­gy, which was patent­ed be­fore the pan­dem­ic when Mod­er­na was de­vel­op­ing an­oth­er mR­NA vac­cine for MERS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.